China Merchants Bank Co., Ltd.

600036.SS Q3 2026

Reported: 2026-11-03

China Merchants Bank’s shares rose 0.6% after earnings, a roughly flat reaction. Revenue and net profit growth improved from the first half, while retail loans contracted and retail NPLs rose.

Key takeaways

First-nine-month net operating income was CNY 264.76 billion, up 5.37% year over year; net profit attributable to shareholders was CNY 116.476 billion, up 2.38%.
Net interest income rose 5.83% to CNY 169.379 billion. NIM was 1.82%, down 5 basis points year over year but flat from the first half and quarter on quarter.
Total loans grew 2.69% to CNY 7.45 trillion, but retail loans fell 1.28% to CNY 3.67 trillion; corporate loans rose 10.59%.
The NPL ratio was 0.94%, unchanged from year-end 2025. Retail NPLs increased 0.11 percentage points to 1.19%, and annualized NPL formation rose to 1.07%.
Retail AUM reached CNY 18.71 trillion, up 9.52% from year-end; income from extensive wealth management grew 11.12% year over year.

View recap

Airtel Africa Plc

AAF.L Q2 2027

Reported: 2026-11-03

Airtel Africa’s shares fell 2.5% after results, a roughly flat reaction that suggests a measured response to strong reported growth alongside higher fuel-cost pressure and accelerated investment. Revenue growth and margin expansion were positives, while the transcript does not provide enough detail on outlook to identify a guidance-related driver.

Key takeaways

Constant-currency revenue grew almost 21%; mobile services revenue rose 18.9%, including 28% growth in data revenue.
Mobile money revenue increased 25.8%, while mobile money customers grew 22.4% to more than 60 million.
EBITDA margin expanded 172 basis points to 50.3%; second-quarter margin reached 50.4%, despite higher fuel costs.
The company invested $657 million in the half, accelerating CapEx for capacity, coverage and new services.
Customer numbers rose 11.6% to 194 million; the interim dividend increased 9.2%.

View recap

AbbVie Inc.

ABBV Q3 2026

Reported: 2026-11-03

AbbVie’s shares rose 1.3%, a roughly flat reaction, as third-quarter revenue and adjusted EPS came in above the company’s expectations and full-year revenue guidance increased. Skyrizi and Rinvoq drove immunology growth, while the call also highlighted continued Humira sales declines.

Key takeaways

Third-quarter revenue was $17.4 billion, up more than 10%; adjusted EPS was $3.82, $0.07 above the company’s guidance midpoint.
AbbVie raised full-year revenue guidance by $200 million, bringing the total increase since the start of the year to $800 million.
Immunology revenue approached $9.2 billion, up 16.6% operationally. Skyrizi sales were nearly $5.8 billion, up 22.9%, and Rinvoq sales were $2.7 billion, up 24.3%.
Humira sales were $683 million, down 30%.
The company announced a 5.2% increase in its quarterly dividend, beginning with the payment in February 2027.

View recap

Credit Agricole S.A.

ACA.PA Q3 2026

Reported: 2026-11-03

Credit Agricole shares fell 2.3% after results, a roughly flat market reaction despite adjusted net income growth. The quarter included significant one-offs, while CASA’s CET1 ratio declined 10 basis points and the planned IKB acquisition carries a further 20-basis-point CET1 impact at closing.

Key takeaways

Excluding the specified exceptional items, net income grew 11% year over year; revenue increased 7.5%, with positive jaws of 5.1 percentage points.
CASA reported an ROTE of 14.2%. Its CET1 ratio was 11.2% at September-end, down 10 basis points from June; group CET1 rose 10 basis points to roughly 17.3%.
Credit Agricole agreed to acquire IKB for around €660 million, targeting a 15% ROI within three years. Closing is planned for the end of the first half of 2027, with an estimated 20-basis-point CET1 impact.
CA Savings had more than 200 new customers per day in Germany; the group is targeting 650 per day by year-end and plans to roll out the platform in Belgium and the Netherlands.
Credit Agricole Deutschland launched in October as an app-first digital bank, while the group also announced new initiatives in natural capital and AI.

View recap

Acerinox, S.A.

ACX.MC Q3 2026

Reported: 2026-11-03

Acerinox shares fell 6.9% after earnings, despite higher EBITDA, with investors likely focused on weak underlying demand, rising energy costs and working-capital pressure that pushed debt to a yearly peak. Management expects working capital to unwind in Q4, but that remains an important caveat to the cash-flow picture.

Key takeaways

Q3 sales were €1.6bn, broadly similar to Q2; EBITDA rose 13% quarter over quarter to €199m, a 12.5% margin.
For the first nine months, sales increased 2% year over year to €4.5bn, while EBITDA rose 46% to €470m.
Operating cash flow was slightly negative in Q3 and slightly positive for the nine months. Management attributed the pressure to working capital, alongside capex and the semiannual dividend.
Debt reached €1.5bn, a peak for the year; management expects it to decline in Q4, mainly as working capital reduces.
Demand remains low in many markets, and energy costs have risen. North America—56% of sales—was stable, while Acerinox’s European business was near EBITDA breakeven; domestic appliances remained weak.

View recap

AstraZeneca PLC

AZN Q3 2026

Reported: 2026-11-03

AstraZeneca’s shares rose 7.0% after earnings, with investors responding to 7% revenue growth, 14% core EPS growth and a pipeline update that added more than $10 billion in non-risk-adjusted peak-sales potential. Growth was broad across key therapy areas, though Farxiga and Brilinta exclusivity losses and volume-based procurement in China remained headwinds.

Key takeaways

For the first nine months, total revenue grew 7% and core EPS increased 14%; revenue growth was 12% excluding Farxiga and Brilinta.
Oncology, rare disease and respiratory & immunology delivered double-digit growth, more than offsetting expected headwinds from Farxiga and Brilinta losses of exclusivity and CVRM.
China growth was affected by volume-based procurement; excluding that impact, revenue grew 13%, with growth across all therapy areas.
The company reported positive results from 12 Phase III programs since February and first approvals for four new medicines, bringing approved new molecular entities to 14.
Management cited more than $10 billion in non-risk-adjusted peak-year sales potential from positive pipeline readouts, while emphasizing continued investment toward its $80 billion revenue ambition for 2030.

View recap

AstraZeneca PLC

AZN.L Q3 2026

Reported: 2026-11-03

AstraZeneca shares rose 6.2% after the company reported 7% revenue growth and 14% core EPS growth for the first nine months, alongside continued pipeline progress. Growth excluding Farxiga and Brilinta was 12%, though the transcript also flags ongoing headwinds from those products’ loss of exclusivity and volume-based procurement in China.

Key takeaways

First-nine-month total revenue grew 7% and core EPS increased 14%; revenue growth was 12% excluding Farxiga and Brilinta.
Oncology, rare disease and respiratory & immunology delivered double-digit growth, more than offsetting expected headwinds from Farxiga and Brilinta losses of exclusivity and CVRM.
China growth remained affected by volume-based procurement; excluding that impact, the company said China grew 13%.
AstraZeneca reported positive results from 12 Phase III programs since its full-year results and first approvals for four new medicines, bringing approved new molecular entities to 14.
Management cited more than $10 billion in non-risk-adjusted peak-year sales potential from recent positive Phase III readouts, while noting that potential depends in part on future labels.

View recap

BP p.l.c.

BP.L Q3 2026

Reported: 2026-11-03

BP’s shares fell 3.9% after earnings, with the $4 billion impairment charge—mainly in transition businesses—highlighting that some investments have not delivered expected returns. The quarter’s higher profit and cash flow were positives, but production was broadly flat and the transcript offers no updated financial outlook ahead of the December strategy update.

Key takeaways

Underlying profit was $8.5 billion, up $2.7 billion from the second quarter; operating cash flow was $14.8 billion, up $4 billion.
Upstream production was 2.2 million barrels of oil equivalent per day, broadly flat quarter on quarter. Upstream plant reliability improved to 95.3%, mainly as North Sea and Indonesia outages recovered.
Refinery throughput was around 1.4 million barrels per day, lower than the prior quarter, reflecting the Gelsenkirchen divestment; refining availability rose to 96.5%, above the company’s 96% target.
BP said financial obligations fell $9.3 billion from the second quarter and around $16 billion since the first quarter, but remain too high. Management intends to prioritize excess cash flow toward settling remaining Deepwater Horizon liabilities.
BP announced a quarterly dividend of $0.0866 per ordinary share. It plans to set out its strategic direction, financial framework, and targets in December.

View recap

Compania de Minas Buenaventura S.A.A.

BVN Q3 2026

Reported: 2026-11-03

Buenaventura’s shares fell 2.7% after earnings, a broadly neutral reaction. Revenue and earnings rose, but investors may have focused on gold production falling 60% year over year, alongside a 21% decline in silver output and ongoing processing constraints at San Gabriel.

Key takeaways

Revenue increased 27% year over year to $545 million; EBITDA from direct operations rose 34% to $261 million, with a 48% margin, and net income increased 50% to $268 million.
Gold production fell 60% to approximately 29,000 ounces; silver output declined 21% to 3.4 million ounces, mainly due to lower planned grades at Yumpag. Copper production rose 7% to 13,600 tonnes.
San Gabriel’s mining rate stabilized at 1,700 tons per day and the ore stockpile reached approximately 100,000 metric tons. Management cited temporary processing constraints; recovery is expected to reach approximately 70% in Q4 2026.
Free cash flow was $242 million, including support from $126 million in dividends received. The company ended September with approximately $1 billion in cash and a net cash position of $307 million.
The board approved an interim dividend of $0.5508 per share or ADS.

View recap

CaixaBank, S.A.

CABK.MC Q3 2026

Reported: 2026-11-03

CaixaBank reported continued loan growth and improving profitability, while customer-fund growth slowed. The stock rose 2.6% after earnings, a relatively muted reaction.

Key takeaways

Performing loans grew 8% year over year; domestic lending growth was 6.4%. Residential mortgages rose 7%, while consumer lending growth decelerated to slightly below 10%.
Customer funds increased 5.6%, with management noting a slowdown, particularly in sight deposits as household savings growth eased. CaixaBank said it continued to gain share in household sight deposits.
Net interest income is growing, with customer spread adjusted for hedges up 2 basis points in the quarter and net interest margin up 3 basis points.
Service revenues grew 7.7% year over year. Management raised its services guidance to about €5.6 billion and its return-on-tangible-equity guidance from above 18% to around 19%.
Asset quality improved, with lower nonperforming loans and assets and coverage at 82%; the interim dividend was set at the upper end of the previously announced range.

View recap

Cameco Corporation

CCJ Q3 2026

Reported: 2026-11-03

Cameco shares fell 12.1% after earnings, with investors likely focused on softer operating guidance and rising costs: production and delivery ranges were narrowed, while direct admin costs and average unit costs of sales increased. Results were lower year over year, though management said that was expected and partly reflected the longer Key Lake maintenance outage and a prior-year Westinghouse payment.

Key takeaways

The company narrowed its 2026 share of uranium production guidance to 19.5–20.5 million pounds and annual delivery guidance to 29.5–30.5 million pounds.
Key Lake’s longer planned maintenance outage reduced production volumes and lifted costs in the quarter; management said the work included projects intended to support long-term operations.
Cameco fine-tuned financial guidance to reflect increased direct admin costs and higher average unit costs of sales. It lowered expected 2026 capital spending because some projects and work were pushed beyond year-end.
Results for the quarter and first nine months were below the same periods last year. The comparisons were also affected by a significant Westinghouse payment received in the prior-year period for the Korean Dukovany project.
The board declared a 2026 annual dividend of CAD 0.24 per share, the same amount paid in 2025.

View recap

Centerra Gold Inc.

CGAU Q3 2026

Reported: 2026-11-03

Centerra’s shares rose 0.7% after earnings, a roughly flat reaction. Operations were generally tracking to plan, while the transcript highlighted lower Mount Milligan cost guidance and progress on growth projects without disclosing enough results here to assess the full quarter.

Key takeaways

Mount Milligan produced more than 44,000 ounces of gold, up 15% from the prior quarter, and 12.8 million pounds of copper. Both metals remain aligned with the mine plan.
Centerra said Mount Milligan remains on track for 2026 guidance of 140,000–155,000 ounces of gold and 50–60 million pounds of copper; strong copper byproduct credits allowed it to lower full-year all-in sustaining cost guidance.
Ixig production is tracking in line with its previously increased full-year production guidance and original cost guidance ranges.
The company repurchased $53 million of shares in Q3, bringing year-to-date buybacks to $125 million.
Goldfield has all major permits in place for the Gemfield deposit, which represents approximately 80% of the project’s life-of-mine production; first production is expected in late 2028.

View recap

Cipher Mining Inc. Common Stock

CIFR Q3 2026

Reported: 2026-11-03

Cipher Digital shares fell 5.9% after the update, with the transcript pointing to a tougher backdrop for new projects: financing markets are more discerning and building costs are rising. Management says it is adjusting lease pricing to protect returns, but the excerpt provides no updated financial outlook or new-lease pricing to show how those pressures will affect growth.

Key takeaways

Three leased campuses total 700 gross MW and represent $16.6 billion of contracted revenue over the next two decades, or about $864 million of projected average annualized NOI.
All three campuses remain under construction; first capacity has been delivered at Black Pearl, with additional capacity across the sites expected to come online in phases over the coming months.
Management cited tighter financing conditions and rising construction costs, and said new leases will be evaluated to ensure returns keep pace with a higher cost of capital.
Cipher reaffirmed its long-term colocation model, emphasizing contracted cash flows from creditworthy tenants rather than taking on the added financing and pricing risks of providing chips directly.

View recap

Canadian National Railway Company

CNI Q3 2026

Reported: 2026-11-03

CN reported higher earnings and free cash flow on volume growth, while reaffirming its full-year EPS outlook. Shares rose 2.2% after the results, a roughly flat reaction that suggests a measured market response.

Key takeaways

EPS grew 18% on 4% volume growth; management reaffirmed mid-to-high single-digit EPS growth for the year on low single-digit RTM growth, saying it was tracking toward the upper end.
Year-to-date free cash flow increased 25%, supported by operating performance and disciplined capital spending; CN continued share repurchases.
Fast Track delivered about CAD 120 million year-to-date, and the company reported record third-quarter fuel efficiency.
CN cited approximately CAD 300 million in new revenues from commercial efforts so far this year, with potential future growth from LNG-related traffic and a planned agreement with Union Pacific to extend its reach into Mexico.

View recap

Covista Inc.

CVSA Q1 2027

Reported: 2026-11-03

Covista’s stock fell 3.5% despite the company raising its fiscal 27 revenue and adjusted EPS guidance. The likely concern is that the outlook remains deliberately cautious for the remaining quarters, leaving investors unconvinced by the quarter’s above-plan performance.

Key takeaways

Q1 revenue rose 10.7% to $512 million; adjusted EBITDA increased 17.1% to $131 million, and adjusted EPS grew 25.1% to $2.19.
Total enrollment reached nearly 105,000, up 7.6% year over year, marking the 13th consecutive quarter of growth.
Management raised fiscal 27 revenue and adjusted EPS guidance, while saying it is taking a prudent view of the remaining quarters.
Chamberlain enrollment grew 1.3%, its third consecutive quarter of growth; Walden posted double-digit enrollment growth for the 10th straight quarter, with undergraduate enrollment up more than 20%.
In medical and veterinary, enrollment rose 3.5%. Management said early starts ahead of federal loan changes lifted the May cycle and made the September class smaller, so it views the two cycles together.

View recap

DaVita Inc.

DVA Q3 2026

Reported: 2026-11-03

DaVita shares fell 3.0% after earnings, with higher-than-forecast technology investment in U.S. dialysis weighing on full-year financial performance. The transcript also points to limited near-term financial contribution from expanded HD: management expects no material net impact on adjusted operating income in 2026 or 2027.

Key takeaways

Q3 adjusted operating income was **$561 million** and adjusted EPS was **$3.82**.
Technology investment was higher than forecast heading into the year and is a drag on full-year performance; management expects its growth to decelerate going forward.
IKC was above plan in Q3, and the company said it was on track to outperform its original full-year guidance.
Expanded HD pilots covered **150 centers** and more than **10,000 patients**; adoption among clinically eligible pilot patients exceeded **90%**. National rollout was due to begin the following week, with most eligible patients expected to transition in November.
Management expects expanded HD’s positive impact from lower mortality and higher volume growth to begin in the **second half of 2028**; it cited a goal of returning to **2% or greater volume growth by 2029**.

View recap

Erste Group Bank AG

EBKDY Q3 2026

Reported: 2026-11-03

Erste Group reported record quarterly revenue and profit, alongside upgraded 2026 targets, while the stock rose 1.9%—a modestly positive reaction. The call also flagged a slight pro forma CET1 decline to 15% and deferred 2027 guidance until the outcome of the Erste Bank Polska tender offer is known.

Key takeaways

Quarterly net interest income rose 5.9%; revenue approached EUR 4.1 billion and operating profit exceeded EUR 2.3 billion.
The cost-income ratio reached a quarterly low of 43.1%; risk costs remained in the low-20-basis-point range.
Erste, excluding Polska, now expects 2026 net interest income growth above 6%, fee growth around 10%, and a cost-income ratio below 46%; group risk costs are expected at the lower end of the 25–30 basis-point range.
Excluding Polska, customer loans grew 5.8% year to date and deposits 4.5%; year-on-year loan growth was 7.7%.
Pro forma CET1 slipped to 15% amid higher risk-weighted assets from model effects. Management held back 2027 guidance pending the Polska tender offer outcome.

View recap

The Estee Lauder Companies Inc.

EL Q1 2027

Reported: 2026-11-03

Despite a 4.1% post-earnings decline, Estée Lauder raised its fiscal 2027 sales and margin outlook after a quarter of broad-based growth and improved profitability. The transcript points to lingering execution risks—particularly Aveda’s supply-chain challenges and Travel Retail’s stabilization—rather than a cut to guidance; it does not establish the specific reason investors sold the stock.

Key takeaways

Organic sales rose 6% and reported sales increased 7%; three of four categories and every region grew.
Fiscal 2027 organic sales guidance increased to 4%–5.5% from 3%–5%; operating-margin expansion guidance rose to 170–250 basis points from 150–230.
Gross margin expanded 240 basis points and operating margin 480 basis points; diluted EPS grew 125%. Consumer-facing investment increased 8%.
Fragrance grew 20% organically, while skin care rose 4%. Makeup recorded a second consecutive quarter of organic growth.
Hair care improved sequentially but remained in modest decline; Aveda faced brand-specific supply-chain logistics challenges.

View recap

Entegris, Inc.

ENTG Q3 2026

Reported: 2026-11-03

Entegris reported record quarterly revenue and higher margins, while the shares were roughly flat, up 0.4% after earnings. The call cited accelerating demand and a larger backlog, alongside an outlook for approximately 8% wafer-start growth in 2026.

Key takeaways

Revenue rose approximately 25% year over year to slightly more than $1 billion; both APS and MS delivered double-digit growth.
Adjusted gross margin reached 48.9%, up more than 500 basis points from a year earlier; adjusted EBITDA margin exceeded 30%.
Unit-driven revenue growth accelerated to 20% in Q3 from approximately 6% in Q1. CapEx-related revenue grew more than 35% in Q3.
Book-to-bill remained significantly above 1; backlog increased more than 35% sequentially and more than doubled year over year.
Management expects approximately 8% wafer-start growth in 2026, but said mainstream utilization remains the most underutilized part of the market.

View recap

First Business Financial Services, Inc.

FBIZ Q3 2026

Reported: 2026-11-03

First Business Financial Services reported record quarterly earnings, 10% annualized loan growth, and 14% annualized core deposit growth. With the stock up 2.2%—a roughly flat reaction—the result was positive but not an unambiguous beat; management noted that loan pipelines had moderated and some of the deposit increase may be temporary.

Key takeaways

EPS rose 6% from the second quarter and 15% year over year; pre-tax, pre-provision earnings increased 13% year over year.
Loans grew 10% annualized quarter over quarter, with commercial real estate the main driver, up about $77 million, or 14% annualized.
Core deposits increased $101 million, or 14% annualized; non-interest-bearing deposits rose $57 million, though management said some balances may be temporary.
The efficiency ratio was 55.12% in the quarter, helped in part by favorable expense timing and net interest margin; management expects it to tick up in the short term as it invests for growth.
Loan pipelines moderated heading into the fourth quarter, but management maintained its target of approximately 10% annual loan growth for 2026 and 2027.

View recap

Federal Realty Investment Trust

FRT Q3 2026

Reported: 2026-11-03

Federal Realty’s shares fell 1.1% after earnings, a roughly flat reaction. The quarter showed improving leasing and higher guidance, but the transcript does not identify a clear source of investor disappointment.

Key takeaways

Reported $1.87 per share, up nearly 6% year over year; management said it tightened and raised full-year guidance, without giving the revised range in the excerpt.
Same-store cash POI growth was 4%.
Comparable leasing deals delivered a 14% cash rent spread across 117 leases, adding $2.6 million in revenue.
The lease rate reached 96.5%; physical occupancy was 93.8%, with roughly 270 basis points of signed leases yet to commence.
The Summit acquisition added 870,000 square feet and 116 tenants. Management cited $508 million invested and projected average POI growth of more than 5% annually over five years.

View recap

Hammond Power Solutions Inc.

HPS-A.TO Q3 2026

Reported: 2026-11-03

Hammond Power Solutions shares fell 9.9% after earnings, with the likely pressure point being softer AEG product activity and a cautious near-term outlook for that business. Management cited Middle East disruption, deferred projects, slower activity in hydrogen and offshore wind, and pricing pressure—despite record consolidated sales and margins.

Key takeaways

Consolidated sales were $446.3 million, more than double the prior-year quarter, and adjusted EBITDA was $84 million; adjusted EPS was $3.13.
Gross margin reached 34.4%. Power Magnetics sales rose approximately 66% year over year to $355.5 million, supported by volume, pricing, and stronger capacity utilization.
Power Magnetics shipments exceeded bookings, reducing backlog modestly from Q2, though it remained approximately 61% above the prior-year level. Management said net bookings increased quarter over quarter.
Integrated Electrical Solutions, primarily AEG, contributed $90.8 million in sales. Service was resilient, but product activity was softer amid project delays, longer sales cycles, and pricing pressure.
HPS announced a Fort Worth facility that will add $250 million of capacity; meanwhile, management described Canada as slower and more competitive and flagged ongoing near-term challenges at AEG.

View recap

The Hershey Company

HSY Q3 2026

Reported: 2026-11-03

Hershey shares fell 2.1% after the earnings call, a roughly flat reaction that suggests a mixed outlook rather than a clear market verdict. Management held its 2027 sales-growth outlook at 2%–4%, but acknowledged that pressured consumer spending could leave growth at the lower end and cited tougher Reese’s Oreo comparisons weighing on Q4 share performance.

Key takeaways

The company maintained its 2027 sales-growth outlook of 2%–4%; it expects low-single-digit carryover pricing, while the consumer and macro backdrop could determine where results land within the range.
Management said Hershey’s brand grew 7% in the last 13 weeks and highlighted three new campaigns, but did not provide a broader share recovery outlook.
Hershey expects a 50% larger innovation pipeline in 2027 versus 2026. Management cited Reese’s Filled Pretzels and Reese’s Oreo as recent innovations, while noting tougher Reese’s Oreo comparisons will affect Q4 performance.
Management said retail performance in Q3 was generally in line with expectations; share momentum accelerated in July and August before slowing against those September comparisons.
The company sees potential for its salty-snacks business to contribute more to both sales and profit in 2027, but gave no figures for that expected contribution.

View recap

Hellenic Telecommunications Organization S.A.

HTO.AT Q3 2026

Reported: 2026-11-03

OTE reported 5% year-on-year revenue growth in the third quarter, with management citing accelerating EBITDA growth and continued momentum in mobile and FTTH. The stock rose 1.5% after earnings, a roughly flat reaction that suggests a measured market response rather than a clear positive or negative verdict.

Key takeaways

Revenue, adjusted for the anticipated phaseout of certain near-zero-margin international wholesale activities, increased 5% year-on-year in Q3; growth was 8.4% for the first nine months.
Including data communications, fixed retail service revenues grew 2.9% year-on-year, while fixed retail service revenues excluding data communications were slightly lower in Q3 and broadly stable over nine months.
Broadband base was broadly stable versus a year ago; FTTH utilization rose on customer additions in both retail and wholesale, and Pay-TV surpassed 800,000 customers.
Mobile saw continued migration from prepaid to postpaid, higher demand for data services, and another quarter of growth in overall mobile base ARPU.
System Solutions delivered what management described as a solid quarter, with the Recovery and Resilience Facility deployment cycle mostly complete; management reiterated its ambition for solid double-digit full-year growth.

View recap

John B. Sanfilippo & Son, Inc.

JBSS Q1 2027

Reported: 2026-11-03

Investors were disappointed by a 14.9% post-earnings stock decline, as sales fell 3.5%, consumer-channel volume weakened, and gross margin compressed amid pricing pressure, higher manufacturing costs, and unfavorable mix. Management cited improving momentum, but the quarter’s weaker profitability and soft demand in key products weighed on the results.

Key takeaways

Net sales declined 3.5% year over year to $288.1 million; weighted average selling price per pound fell 3.6%, mainly due to product mix and lower commodity-related prices.
Consumer distribution volume decreased 6.7%, including a 6.3% drop in private-brand volume. Management cited category softness, reduced promotions, and previously lost business; mainstream bar softness also hurt sales.
Gross profit fell 9.6% to $48.9 million, and gross margin declined to 17% from 18.1%. The company attributed the pressure to competitive pricing, timing of pricing actions, higher freight and other manufacturing costs, and unfavorable mix.
Volume increased 3.7% in commercial ingredients and 41.3% in contract manufacturing, though the latter reflected higher snack-nut sales to an existing customer and was partly offset by a non-repeat of prior-year granola sales.
Management said sales volume was unchanged from the prior-year period and highlighted new retail distribution and traction for its OVH Go Go Protein snack item, while noting inflation and consumer sentiment remain challenges.

View recap

Krystal Biotech, Inc.

KRYS Q3 2026

Reported: 2026-11-03

Shares fell 11.0% after earnings, with the clearest concern being delayed timing for some clinical readouts: management said results are now expected in the upcoming months, later than hoped. That pipeline uncertainty weighed against continued commercial growth and profitability.

Key takeaways

VYJUVEK revenue was $127.3 million, up 30% year over year; international revenue was $32 million and U.S. net revenue was $95.3 million.
The company reported diluted EPS of $2.05 and ended September with $1.2 billion in cash and investments.
Management updated timing for some clinical readouts, saying results are expected in the upcoming months; it did not provide specific dates on this call.
International access progressed: pricing negotiations concluded in Italy, with launch expected in early 2027; Spain pricing discussions are ongoing, with a decision expected before year-end.
The board authorized a share repurchase program of up to $400 million, expected to be deployed over the next two years.

View recap

Mondelez International, Inc.

MDLZ Q3 2026

Reported: 2026-11-03

Mondelez shares rose 3.9% after earnings. The call’s positive signals included maintained 2026 outlook and management’s confidence in strong 2027 EPS growth, alongside volume growth in Europe and continued North American momentum.

Key takeaways

Management maintained its 2026 top-line and EPS outlook, while saying Middle East conflict-related costs are being absorbed within that outlook.
Management expects strong EPS growth in 2027, supported by volume-led growth, productivity savings, and continued momentum in emerging markets and the U.S.; it also flagged inflation in freight and some commodities.
Europe posted 1.6 percentage points of positive volume/mix growth, which management described as broad-based; unusually hot weather reduced growth by 1%.
Emerging-market conditions were mixed: India was positive and Latin America solid, while China was softer. Management cited about 130,000 additional outlets in India year to date and more than 1 million stores in Brazil.
North American consumer confidence remains soft, and the CEO said he does not expect it to improve soon; management nevertheless said the business grew share and top line.

View recap

Mapletree Commercial Trust

N2IU.SI Q2 2027

Reported: 2026-11-03

MPACT’s roughly flat share reaction, up 1.8%, reflects a mixed first half: Singapore growth and lower financing costs partly offset falling revenue and NPI, with overseas properties under pressure. China and Hong Kong conditions, longer downtime and negative rental reversions remain key concerns.

Key takeaways

First-half gross revenue fell 5.3% year on year to $413.9 million; NPI declined 6.5% to $308.3 million. Second-quarter revenue and NPI were down 5.0% and 6.3%, respectively.
Singapore gross revenue grew 1.2% in the first half. VivoCity revenue rose 7.5% and NPI 6.9%, benefiting from the B2 AEI; VivoCity reported 15% rental reversion so far this year.
Overseas contributions were hurt by the Fujitsu Building nonrenewal, challenging conditions in China and Hong Kong, longer downtime and a stronger Singapore dollar against the yen and Hong Kong dollar. China leasing remains challenging, while Festival Walk rental reversions remain weak.
First-half DPU was $0.0390; second-quarter DPU was $0.0194. Lower finance expenses—down 14.4% to $83.4 million for the first half—partly cushioned weaker property contributions.
MBC committed occupancy increased from 94.3% to 95.4%, with new leases expected to contribute progressively from the third quarter. Aggregate leverage was 38.1%, and interest coverage was 3.3x.

View recap

Napco Security Technologies, Inc.

NSSC Q1 2027

Reported: 2026-11-03

NAPCO shares fell 18.4% after earnings, with softer equipment revenue the clearest likely disappointment: management attributed it to lower purchases from two locking distributors, despite higher end-customer sales. Recurring revenue continued to grow, but the quarter’s equipment weakness may have raised concern about near-term growth.

Key takeaways

Annualized recurring revenue run rate reached approximately **$106 million**, up **$3 million** from the level reported in August; recurring service revenue grew at a double-digit rate.
Recurring service gross margins remained **above 90%**.
Equipment revenue was softer, primarily due to purchasing patterns at two locking distributors; management said those distributors’ combined end-customer sales increased year over year and sequentially.
Management emphasized that distributor inventory and purchasing decisions can affect quarterly equipment revenue, while maintaining a healthy, growing equipment business remains a priority.

View recap

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

OMAB Q3 2026

Reported: 2026-11-03

OMA’s shares rose 4.8% after earnings, with adjusted EBITDA up 8.7% and the margin at 75%. Passenger growth was modest at 1.3%, but commercial and diversification revenue growth helped support the quarter.

Key takeaways

OMA served 7.7 million passengers, up 1.3% year over year; domestic traffic rose 0.6% and international traffic increased 6%.
Total aeronautical and non-aeronautical revenue grew 8.3% to MXN 3.8 billion. Commercial revenue rose 11%, while diversification revenue increased 20.4%.
Adjusted EBITDA increased 8.7% to MXN 2.9 billion, with a 75% margin. Cost of services and G&A rose 8.6%, including higher payroll and contracted services costs.
Net income increased 2.9% to MXN 1.6 billion; financing expense rose 16.5% to MXN 348 million, mainly due to higher average debt.
Quarter-end cash was MXN 4 billion, total debt was MXN 14.9 billion, and net debt-to-adjusted EBITDA stood at 1.0x.

View recap

Public Service Enterprise Group Incorporated

PEG Q3 2026

Reported: 2026-11-03

PSEG reported third-quarter non-GAAP operating earnings of $1.15 per share and reaffirmed its full-year guidance. The stock was roughly flat after earnings (+0.1%), reflecting a neutral market reaction.

Key takeaways

Third-quarter net income was $0.76 per share; year-to-date non-GAAP operating earnings were $3.56 per share.
PSEG reaffirmed full-year 2026 non-GAAP operating earnings guidance of $4.28–$4.40 per share.
Utility-margin growth from energy-efficiency and transmission investments was offset by higher depreciation and interest costs, as well as tax timing.
PSEG Power’s results improved with higher realized market prices and nuclear generation, gas operations, and lower O&M following the absence of the prior-year Hope Creek refueling outage.
PSEG Nuclear delivered 8.2 TWh during the quarter at a 95.5% capacity factor; Salem Unit 1 entered a refueling outage after a 491-day run.

View recap

PUMA SE

PUM.DE Q3 2026

Reported: 2026-11-03

PUMA’s shares rose 7.3% after earnings, with the quarter showing signs of sequential improvement and momentum in running and Asia Pacific. However, sales remained down 6.3% year over year, and higher operating expenses more than offset gross-margin improvement.

Key takeaways

Currency-adjusted sales fell 6.3% year over year, improving versus Q2; management attributed the decline mainly to ongoing reset measures and weaker consumer demand.
Asia Pacific and e-commerce each delivered double-digit growth, while running grew by double digits and training by single digits.
Reported EBIT was down 11.4%; the gross-profit-margin improvement versus last year was more than offset by a higher OpEx ratio.
Q3 cash flow was €92 million despite lower profitability, supported by improved working-capital management.
Management said PUMA remained on track with its plans for the year, while describing recovery as gradual and 2023 as a transition year toward a return to growth in 2027.

View recap

Sanofi

SAN.PA Q3 2026

Reported: 2026-11-03

Sanofi shares rose 5.9% after earnings, as Q3 sales grew 14.3% to €14.4 billion and management outlined expanded access to immunology compounds through its Regeneron alliance. The longer-term picture still hinges on replenishing the pipeline and managing Dupixent’s loss of exclusivity.

Key takeaways

Q3 sales were €14.4 billion, up 14.3% year over year.
Sanofi discontinued amlitelimab and itepekimab as part of pipeline optimization.
The expanded Regeneron alliance gives Sanofi access to four new immunology compounds; the company aims to launch its long-acting anti-IL-13 medicine ahead of Dupixent biosimilars.
Management says Dupixent’s loss of exclusivity is a top priority and expects only a moderate impact on total group revenue, while focusing on preserving earnings and cash flow.
Sanofi plans to use business development and M&A, particularly late-stage or commercial opportunities, to support growth in immunology, rare diseases, and vaccines.

View recap

Sanofi

SNY Q3 2026

Reported: 2026-11-03

Sanofi’s shares rose 5.6% after earnings, as Q3 sales grew 14.3% to €14.4 billion. The company also reaffirmed its focus on growth through Dupixent’s loss of exclusivity, backed by expanded Regeneron collaboration and planned business development.

Key takeaways

Sanofi reported Q3 sales of €14.4 billion, up 14.3% year over year.
Management named immunology, rare diseases, and vaccines as its strategic focus areas.
Sanofi discontinued amlitelimab and itepekimab as part of pipeline optimization.
The expanded Regeneron alliance adds access to four immunology compounds; Sanofi aims to launch a long-acting anti-IL-13 for atopic dermatitis ahead of Dupixent biosimilars.
Management expects Dupixent’s loss of exclusivity to affect group revenue only moderately, while prioritizing preservation of earnings and cash flow.

View recap

Tempus AI, Inc. Class A Common Stock

TEM Q3 2026

Reported: 2026-11-03

Tempus gained 8.7% after reporting Q3 revenue growth of 23%, positive adjusted EBITDA, and higher 2026 revenue guidance. The quarter’s strongest growth came from oncology volume and Data and Apps, while hereditary cancer testing remains an area to watch.

Key takeaways

Revenue was $412 million, up 23% year over year; diagnostics contributed $304 million, up 20%, and Data and Apps contributed $108 million, up 33%.
Oncology revenue rose 28% to $173 million, with volume up 32%. Hereditary cancer testing revenue was $111 million; management said the business appears poised to do better, but the call excerpt does not provide a 2027 outlook.
Adjusted EBITDA was $25.6 million, and cash and marketable securities totaled $854 million at quarter-end.
Tempus raised 2026 revenue guidance to $1.6 billion and maintained its expectation of approximately $65 million in adjusted EBITDA.
The BMS and Pathos agreements are expected to generate $193 million of additional Data and Apps revenue over approximately five years.

View recap

TDK Corporation

TTDKY Q2 2027

Reported: 2026-11-03

TDK shares fell 9.7% after the earnings release, despite record first-half results, as investors focused on weaker-than-expected ICT device production in the second half and the risk it poses to smartphone-related demand. AI data-center sales are tracking ahead of expectations, but that strength may not fully offset the softer ICT outlook.

Key takeaways

First-half net sales rose 31.9% to ¥1,560.6 billion and operating profit increased 41.0% to ¥208.2 billion; both were record highs. The company cited positive foreign-exchange effects of ¥134.4 billion on sales and ¥19.9 billion on operating profit.
Management expects second-half ICT device production, including smartphones, to be lower than initially projected. It said AI ecosystem sales are ahead of expectations and should remain solid.
Energy Application Products, TDK’s largest segment, posted sales of ¥867.7 billion, up 33.9%, and operating profit of ¥150.1 billion, up 9.1%. Rechargeable-battery sales benefited from product mix and price revisions despite lower volume from reduced ICT production.
Magnetic Application Products benefited from AI-data-center-driven HDD demand: segment sales rose about 1.5 times year on year, operating profit 2.8 times, and head and suspension volumes increased 38% and 34%, respectively.
Passive Components sales rose 25.3% to ¥358 billion, while operating profit increased 2.7 times to ¥39.6 billion, supported by AI data-center and automotive demand.

View recap

Unicaja Banco, S.A.

UNI.MC Q3 2026

Reported: 2026-11-03

Unicaja reported continued growth in lending and customer funds, alongside higher nine-month net income and a larger interim dividend. With the stock up 2.1%, the reaction was roughly flat: the positives were balanced by pressure on CET1 and management’s comment that near-term sensitivity to interest rates is very small.

Key takeaways

Nine-month net income was €543 million, up 8% year over year; adjusted return on tangible equity was 12.2%.
Performing loans grew 5% year over year, led by corporate loans at 11%; total customer funds increased 4.6%, including 14% growth in mutual funds.
Assets under management and insurance revenues rose 9% year over year and represented 19% of total revenues. Net inflows reached €1.6 billion, a 15% market share.
The NPL ratio fell to 1.8% from a year earlier, while coverage rose to 85% from 74%; cost of risk was 19 basis points.
CET1 declined to 15.5% during the quarter. The bank announced a €0.0642 second interim dividend, with 2026 interim dividends totaling €382 million, up 126% year over year.

View recap

World Kinect Corporation

WKC Q3 2026

Reported: 2026-11-03

World Kinect reported a mixed quarter, with marine benefiting from market volatility while aviation faced other factors that weighed on results. The stock was roughly flat, up 0.3% after earnings.

Key takeaways

Management described aviation trends as healthy, citing commercial passenger activity in Western Europe and Latin America and global cargo growth; commercial trip support improved year over year.
Marine delivered another strong quarter, partly benefiting from fuel prices and volatility that were higher than management had anticipated in late July.
Land is shifting from portfolio simplification toward profitable growth, with a focus on retail and cardlock, pricing, productivity, and operating efficiency.
Management said the company generated solid cash flow and highlighted disciplined cost management and higher returns on capital as priorities.
The excerpt ends mid-sentence as management discusses conditions entering the final quarter, so it does not provide the full outlook.

View recap

Earnings Recaps

China Merchants Bank Co., Ltd.

Airtel Africa Plc

AbbVie Inc.

Credit Agricole S.A.

Acerinox, S.A.

AstraZeneca PLC

AstraZeneca PLC

BP p.l.c.

Compania de Minas Buenaventura S.A.A.

CaixaBank, S.A.

Cameco Corporation

Centerra Gold Inc.

Cipher Mining Inc. Common Stock

Canadian National Railway Company

Covista Inc.

DaVita Inc.

Erste Group Bank AG

The Estee Lauder Companies Inc.

Entegris, Inc.

First Business Financial Services, Inc.

Federal Realty Investment Trust

Hammond Power Solutions Inc.

The Hershey Company

Hellenic Telecommunications Organization S.A.

John B. Sanfilippo & Son, Inc.

Krystal Biotech, Inc.

Mondelez International, Inc.

Mapletree Commercial Trust

Napco Security Technologies, Inc.

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

Public Service Enterprise Group Incorporated

PUMA SE

Sanofi

Sanofi

Tempus AI, Inc. Class A Common Stock

TDK Corporation

Unicaja Banco, S.A.

World Kinect Corporation

Community

Earnings Recaps

China Merchants Bank Co., Ltd.

Airtel Africa Plc

AbbVie Inc.

Credit Agricole S.A.

Acerinox, S.A.

AstraZeneca PLC

AstraZeneca PLC

BP p.l.c.

Compania de Minas Buenaventura S.A.A.

CaixaBank, S.A.

Cameco Corporation

Centerra Gold Inc.

Cipher Mining Inc. Common Stock

Canadian National Railway Company

Covista Inc.

DaVita Inc.

Erste Group Bank AG

The Estee Lauder Companies Inc.

Entegris, Inc.

First Business Financial Services, Inc.

Federal Realty Investment Trust

Hammond Power Solutions Inc.

The Hershey Company

Hellenic Telecommunications Organization S.A.

John B. Sanfilippo & Son, Inc.

Krystal Biotech, Inc.

Mondelez International, Inc.

Mapletree Commercial Trust

Napco Security Technologies, Inc.

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

Public Service Enterprise Group Incorporated

PUMA SE

Sanofi

Sanofi

Tempus AI, Inc. Class A Common Stock

TDK Corporation

Unicaja Banco, S.A.

World Kinect Corporation

Community

Trending This Week

Notifications